Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...

Table 2. Definition of Response to First-Line TKI Treatment According to ELN 2013, 4 Compared with the Equivalent Definitions Of NCCN 1.2014 5 Table 3. Summary of the Main Studies Reporting a ...

Philadelphia, March 27, 2025 – Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), ...

Leukemia is an umbrella term for multiple different cancers that form in the blood, one such member of the leukemia family being chronic myelogenous leukemia (CML). CML is caused by a chromosomal ...

Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation ...

Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study ...

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial ...

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms According to the publication’s authors: "Its ease of use facilitates ...

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty ...